Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients
- Registration Number
- NCT02920801
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Brief Summary
In this study, the investigators aim to investigate whether saxagliptin modulate endothelial progenitor cells number and flow-mediated dilation in newly diagnosed, treatment-naive type 2 diabetic patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- newly diagnosed type 2 diabetics (diagnosis were made according to the American Diabetes Association Guideline [19] ), treatment naive, age 30-75, hemoglobin A1c (HbA1c) ≥6.5%, fasting c-peptide >1.0ng/L
Exclusion Criteria
- pregnancy or lactation, smoker, acute disease or infection, chronic renal disease (estimated glomerular filtration rate <60 mL/min/1.73m2), live enzymes 3 times above the normal range, positive islet autoantibody, fasting c-peptide <1.0ng/L, severe hypertriglyceridemia (triglyceride >5.6mmol/L), cardiovascular events or surgery within 3 months, taking glucocorticoid, history of acute or chronic pancreatitis, pancreatic tumor, severe cardiac or pneumonic disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description metformin group Metformin metformin group consumed metformin 1500mg per day for 12 week saxagliptin group saxagliptin saxagliptin group consumed saxagliptin 5mg per day for 12 week
- Primary Outcome Measures
Name Time Method endothelial progenitor cell 12weeks flow-mediated dilation 12weeks
- Secondary Outcome Measures
Name Time Method fasting blood glucose 12weeks HbA1c 12weeks liver function test 12weeks renal function test 12weeks 2 hour postprandial blood glucose 12weeks
Trial Locations
- Locations (1)
Fang Li
🇨🇳Shanghai, Shanghai, China